SYN-AKE
Dipeptide Diaminobutyroyl Benzylamide Diacetate
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a healing & recovery research compound. Topical anti-wrinkle peptide — a synthetic snake-venom (waglerin-1) mimetic that blocks muscle nicotinic receptors to relax expression lines.
SYN-AKE quick facts
| Reported research dose | Topical, as directed |
| Route | Topical |
| Frequency | 1-2x Daily (topical) |
| Half-life | N/A (topical) |
| Forms | Topical |
| Evidence level | Cosmetic/topical |
Snake-venom-mimetic wrinkle peptide. Topical only, novelty-strong.
How SYN-AKE works
Topical anti-wrinkle peptide — a synthetic snake-venom (waglerin-1) mimetic that blocks muscle nicotinic receptors to relax expression lines.
Proposed benefits
Expression-line relaxation and skin smoothing (cosmetic).
Where to get SYN-AKE
Buy SYN-AKE at Ion Peptide →The evidence for SYN-AKE
Graded by what exists behind each claim.
✅ Clinically validated
- Manufacturer studies report reduced wrinkle depth with topical application. No independent randomized data, which for a cosmetic peptide is the norm rather than the exception — the ingredient supplier funds the study, the formulator cites it, and nobody outside that chain has replicated it.
📊 Correlative data
- Used in anti-ageing serums, marketed on the snake-venom analogy. Reported experience is in line with the other topical neuropeptides — subtle.
🧪 Theoretical / extrapolated
- A dipeptide mimicking waglerin-1 from the temple viper, which antagonizes the nicotinic acetylcholine receptor at the neuromuscular junction — a different site from the Argireline family's SNARE interference.
- Same fundamental problem regardless of the mechanism: the target is below the dermis and the molecule is applied above it.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What SYN-AKE actually does
SYN-AKE is sold as a synthetic mimic of waglerin-1, a snake venom peptide. The published pharmacology of waglerin-1 is excellent, it is worth knowing, and once you know it the mimicry claim becomes very hard to sustain.
What waglerin-1 actually does, measured. It blocks the muscle nicotinic acetylcholine receptor at the neuromuscular junction, and it does so with a subunit selectivity that is unusually clean. The adult muscle receptor carries an ε subunit; the fetal and neonatal receptor carries γ instead. Waglerin-1 blocked the endplate response to iontophoretic acetylcholine in adult wild-type mice with an IC50 of 50 nM. At 1 µM it reduced the acetylcholine response to 4 ± 1% of control in adult animals — and to only 73 ± 2% in wild-type pups less than 11 days old, with no effect at all in adult mice genetically lacking the ε subunit. The suppression appeared abruptly between days 11 and 12 after birth, which is when the γ-to-ε switch happens, and waglerin-1 reduced α-bungarotoxin binding at adult but not neonatal endplates McArdle 1999.
That is a textbook demonstration of a toxin reading one subunit. It is also the reason waglerin-1 is lethal to adult mice and not to neonatal ones.
Now the structural question, which is the one that decides this page: how much peptide do you need to do that? Waglerin-1 is a 22-residue peptide held in shape by a disulfide bridge. The best available answer to the minimum-size question comes from azemiopsin, a closely related viper peptide that does the same job without any disulfide — the first natural toxin known to block nicotinic receptors with no cysteines at all. Azemiopsin is 21 residues (DNWWPKPPHQGPRPPRPRPKP), adopts a β-structure, competes with α-bungarotoxin at Torpedo receptor with an IC50 of 0.18 ± 0.03 µM, and blocks human muscle-type receptor more potently in the adult (α1β1εδ) form, EC50 0.44 ± 0.1 µM, than the fetal (α1β1γδ) form at 1.56 ± 0.37 µM. It shares a homologous C-terminal hexapeptide with waglerin Utkin 2012.
And here is the number that settles it. Alanine scanning of azemiopsin found that the residues at positions 3–6, 8–11 and 13–14 are essential for binding Utkin 2012. That is ten specific side chains distributed across fourteen residues. SYN-AKE is a dipeptide — dipeptide diaminobutyroyl benzylamide diacetate, two residues plus a benzylamide cap. Two side chains cannot present a pharmacophore that requires ten, spread over a β-structured backbone fourteen residues long. This is not an argument from skepticism; it is the originating literature’s own structure-activity data applied to the marketed molecule, and nobody applies it.
The shared hexapeptide is the strongest thing the mimicry claim has, and it is still six residues, not two. Azemiopsin and waglerin share a homologous C-terminal hexapeptide Utkin 2012, and waglerins and azemiopsin are grouped together as short peptide neurotoxins found in otherwise hemotoxic viper venoms Osipov 2023. If a minimal waglerin pharmacophore exists, six residues is the published lower bound, and it has never been shown that a hexapeptide alone retains activity — let alone a dipeptide.
What has never been published for this ingredient. No receptor binding constant. No IC50 at any nicotinic receptor. No electrophysiology. There is no published measurement of SYN-AKE at the target it is named for, in any preparation, at any concentration. The claim is entirely structural analogy.
Cell, rodent, human — and where it stops
Step one, the toxin in animals: excellent, and it is not this molecule. Waglerin-1 at the mouse endplate, IC50 50 nM, ε-subunit selective, verified against a knockout McArdle 1999. Azemiopsin at human muscle-type receptor expressed in Xenopus oocytes, EC50 0.44 µM adult form, with alanine scanning of the pharmacophore Utkin 2012.
Step two, the dipeptide in cells: nothing. No published cell or receptor assay of dipeptide diaminobutyroyl benzylamide diacetate exists in the indexed literature.
Step three, the dipeptide in animals: nothing.
Step four, humans — one indexed study, and it cannot isolate the ingredient. A PubTator3 search of the NCBI corpus for dipeptide diaminobutyroyl benzylamide diacetate on 4 September 2026 returned ten documents; nine are reviews, ingredient overviews or studies of other products. One is a primary clinical study, and it tests a serum containing five actives: acetyl hexapeptide-8, the dipeptide, gluconolactone, niacinamide and laminaria extract. An ex vivo arm measured matrix metalloproteinase-1, elastic fibers and collagen types I, III, IV and XVII; two clinical arms enrolled n = 50 for static wrinkles and n = 42 for dynamic wrinkles Zhu 2026.
The results of that study contain the single most damaging observation on this page, and it is in the study’s own abstract. After 12 weeks, mean clinical scoring improved 35% to 69% for static wrinkles — and only 10% to 13% for dynamic wrinkles, all p < 0.001 Zhu 2026.
Static wrinkles are the ones present at rest: photoageing, collagen loss, glycation. Dynamic wrinkles are the ones made by muscle contraction — the expression lines a neuromuscular blocker is supposed to relax. A serum containing two peptides both marketed as neuromuscular relaxants improved the muscle-independent wrinkles three to six times more than the muscle-dependent ones. That is the opposite of what the mechanism predicts. It is entirely consistent with niacinamide, gluconolactone and hydration doing the work, and it is reported by the study that the ingredient’s own field would cite in its favor.
The obstacles, named one at a time. (1) No study of the ingredient alone has ever been published — the one indexed clinical study tests it inside a five-active formula Zhu 2026, so its individual contribution is unrecoverable by any analysis. (2) The evidence the vendors cite is supplier material. Wrinkle-depth reductions attributed to this ingredient come from the raw-material manufacturer’s own studies, which are not indexed in PubMed, carry no PMID, and have never been independently replicated. Saying that plainly is the finding. It is not an accusation — supplier-funded, unpublished efficacy data is the normal state of the cosmetic ingredient market, and a reader deciding what to buy deserves to know that the tier of evidence here is different in kind from a randomized trial. (3) The target is anatomically out of reach, which is the next section. (4) No dose-response, no duration-response, and no vehicle comparison has been published at any concentration.
SYN-AKE pharmacokinetics — how much of it actually gets in
The catalog says ‘N/A (topical)’. For this compound the arithmetic produces a genuinely surprising answer: the skin barrier is not the problem. The anatomy is.
Step 1: the barrier, which this molecule clears. Computed from the INCI name — two amino acid residues, a benzylamide cap and two acetate counter-ions — the salt weighs roughly 450 Da. The 500 Dalton rule says a compound must be under 500 Da to be absorbed through the corneal layer Bos 2000. This one is under it, which puts it in a completely different position from the decapeptide on the neighboring page, and it means the usual ‘peptides do not penetrate’ objection does not apply here.
Step 2: how much is applied. Cosmetic use levels for this ingredient are stated by the raw-material supplier rather than in the literature, so take a deliberately generous 0.05% active. That is 500 µg/g, or about 1.1 mM in the cream. At a typical facial application of 1 mg of product per cm², that is 0.5 µg/cm² on the surface.
Step 3: what reaches the living epidermis. For a sub-500 Da molecule, 10% penetration is a defensible estimate, giving 0.05 µg/cm² into a viable epidermis about 100 µm thick — roughly 5 µg/mL, or about 11 µM. Against azemiopsin’s EC50 of 0.44 µM at the adult human muscle receptor Utkin 2012, that is a concentration 25 times higher than the active range of a real toxin. On concentration grounds alone, this ought to work.
Step 4: and this is where it stops, twice over.
(a) The receptor is not in the epidermis. The neuromuscular junctions of the facial mimetic muscles sit 1 to 3 millimetres below the skin surface, beneath the entire dermis. The 11 µM computed above is a concentration at 0.1 mm. To reach a motor endplate the molecule must travel ten to thirty times further, through collagenous dermis, against no concentration gradient once the epidermis equilibrates.
(b) The dermal capillaries take it away, and this is the argument nobody makes. The papillary dermis carries a dense capillary plexus at roughly 100–200 µm depth — immediately below the epidermis and far above the muscle. Anything small enough to cross the stratum corneum is small enough to be swept into that plexus and carried into the systemic circulation. That is precisely why transdermal patches work for systemic drugs and why no topical delivers a small molecule to a muscle underneath it. The property that lets this dipeptide penetrate is the same property that guarantees it will be cleared before it arrives.
The comparison that proves the point. Botulinum toxin, the only agent that reliably relaxes facial expression lines, is a 150,000 Da protein — three hundred times over the 500 Dalton limit Bos 2000 — and it is injected directly into the muscle. It is injected because there is no other route to the neuromuscular junction, and that is true regardless of what the molecule weighs.
What degrades it. Skin is proteolytically active, and small unmodified peptides are degraded in it; the dermal-stability and permeation work that exists for other cosmetic peptides Choi 2014 has never been done for this one. Systemic exposure after topical use has never been measured. There is no injectable form, no oral form, and no first-pass question to answer — nobody has proposed a route other than a cream.
What would have to be true, and how you would know it was not
Three predictions. There is no blood test for a wrinkle, so the falsification is what to watch, how long before it means anything, and what will fool you. The first prediction argues against the product and it has already been tested by accident.
1. Dynamic wrinkles should improve LESS than static ones — and they did. If the neuromuscular mechanism worked, expression lines would be the ingredient’s best category. In the only indexed clinical study containing it, static wrinkles improved 35% to 69% and dynamic wrinkles 10% to 13% Zhu 2026. What to watch: photograph your own face twice at each visit — fully relaxed, then at maximum frown or maximum smile — same distance, same light, same expression effort. A neuromuscular agent must narrow the gap between the two photographs. A moisturizer improves only the relaxed one. That single paired photograph separates the two mechanisms, and no published study of this ingredient has ever reported it.
2. Nothing should happen quickly, and if it does it is the vehicle. How long before it means anything: the clinical study reported static wrinkle improvement within the first week Zhu 2026. Nothing that happens in a week is collagen and nothing that happens in a week is a receptor blockade at a neuromuscular junction — it is stratum corneum hydration, which flattens fine lines within hours and reverses within hours of stopping. Twelve weeks is the minimum honest interval, and the comparison has to be against the same base cream without the peptide.
3. What will fool you, and there are four things. Hydration — the single largest short-term effect of any facial product, and it is indistinguishable from a wrinkle improvement in a photograph. The rest of the formula — the one clinical study ran five actives together, including niacinamide and an exfoliating polyhydroxy acid Zhu 2026, either of which outperforms an unproven dipeptide on published evidence. Lighting and angle — a change of ten degrees in light direction changes apparent wrinkle depth more than twelve weeks of any cosmetic. And the supplier’s own before-and-after images, which are the source of essentially every efficacy claim made for this ingredient and are not indexed anywhere a reader can check them.
What nobody has tested yet
Four experiments. The first is one afternoon of work and would settle the entire question.
1. Nobody has ever put this molecule on a nicotinic receptor. The assays are standard and both were used on the real toxins — endplate electrophysiology McArdle 1999, α-bungarotoxin competition and two-electrode voltage clamp in Xenopus oocytes expressing human muscle-type receptor Utkin 2012. Running dipeptide diaminobutyroyl benzylamide diacetate through either would produce the first receptor measurement this ingredient has ever had. An IC50, or the absence of one, would settle a claim that has been sold for two decades on structural analogy alone.
2. Nobody has established the minimum waglerin pharmacophore. Alanine scanning of azemiopsin identified essential residues at positions 3–6, 8–11 and 13–14, and the shared waglerin homology is a C-terminal hexapeptide Utkin 2012. Nobody has synthesized that hexapeptide alone, or a pentapeptide, or a tripeptide, and walked the activity down to find where it disappears. That truncation series is a classic, cheap experiment; it would tell the whole cosmetic peptide field where the floor is, and it has not been published.
3. Nobody has measured whether it reaches muscle. No permeation study, no depth profile, no tape-strip recovery, no measurement in dermis or in muscle after topical application. The arithmetic on this page says the dermal capillary plexus intercepts it long before the neuromuscular junction; that is a prediction from anatomy, not a measurement, and a radiolabelled depth profile in excised human skin would replace it with a number.
4. Nobody has run it against its own vehicle. Every efficacy claim compares a finished product to baseline or to no treatment Zhu 2026. A split-face trial of the identical base cream with and without the dipeptide is the only design that isolates the ingredient, it is well within the budget of any raw-material supplier, and in more than twenty years of sale it has not appeared in the indexed literature.
SYN-AKE — its own safety story, not its class's
The shared block on this page is a healing-and-recovery safety profile written for injected peptides. For a topical dipeptide it is the wrong document, and the real safety story here has an unusual shape: the reasons to think it is safe are the same reasons to think it does not work.
1. If it did what it claims, it would be a neuromuscular blocking agent. That is not rhetoric — waglerin-1 blocks the adult muscle acetylcholine receptor with an IC50 of 50 nM and kills adult mice, sparing neonates only because their receptors still carry the γ subunit McArdle 1999. A molecule that genuinely reproduced that pharmacophore and genuinely reached muscle would carry a real risk of unwanted weakness, and the compound’s excellent tolerability record is direct evidence that it does neither.
2. The tolerability record itself is real but shallow. The one indexed clinical study reports no safety concerns across n = 50 and n = 42 arms over 12 weeks Zhu 2026 — for a five-active serum, not for this ingredient. Everything else is supplier data with no PMID. So the honest statement is: no signal has been reported, and fewer than 100 people have ever been studied using anything containing it in the indexed literature.
3. The risks that do apply are formulation risks. Contact dermatitis and irritation from preservatives, fragrance, alcohol and the other actives; in the study formula, gluconolactone is an exfoliating polyhydroxy acid and niacinamide can flush Zhu 2026. Periocular application — where this ingredient is most often used, because that is where expression lines are — puts all of that on the thinnest skin on the body, a few millimetres from the eye.
4. The snake-venom framing is marketing, and it cuts both ways. Waglerins and azemiopsin are genuine short peptide neurotoxins found in the venoms of vipers whose venom is otherwise hemotoxic Osipov 2023. Nothing of that venom is in the jar: the ingredient is a synthetic dipeptide, not an extract, and it carries no venom-derived contamination risk. People worried about putting snake venom on their face are worried about the wrong thing; the thing worth knowing is that it is not venom-like either.
What zero means. There are 0 published receptor measurements, 0 published permeation studies and 0 published trials of this ingredient alone. Its clean record is the record of a molecule nobody has looked at hard, and that is different from a molecule that has been looked at and found safe.
Sources read for this page
- McArdle JJ, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. Journal of Pharmacology and Experimental Therapeutics 1999 · PMID 10087048
- Utkin YN, et al. Azemiopsin from Azemiops feae viper venom, a novel polypeptide ligand of nicotinic acetylcholine receptor. Journal of Biological Chemistry 2012 · PMID 22613724
- Osipov A, et al. What Are the Neurotoxins in Hemotoxic Snake Venoms?. International Journal of Molecular Sciences 2023 · PMID 36769242
- Zhu M, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science 2026 · PMID 41668671
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 2000 · PMID 10839713
- Choi YL, Park EK, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules and Therapeutics 2014 · PMID 25143811
SYN-AKE — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
SYN-AKE — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — SYN-AKE in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside SYN-AKE
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
SYN-AKE — frequently asked questions
What is SYN-AKE?
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a healing & recovery research compound. Topical anti-wrinkle peptide — a synthetic snake-venom (waglerin-1) mimetic that blocks muscle nicotinic receptors to relax expression lines.
Is the full SYN-AKE protocol on this page?
The reported research dose is on this page, along with how SYN-AKE works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of SYN-AKE?
SYN-AKE has an approximate half-life of N/A (topical), which is part of what determines how often it's dosed.
What's the evidence behind SYN-AKE?
Current evidence level: Cosmetic/topical. SYN-AKE is offered for research purposes only and is not an approved medicine.
SYN-AKE inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What SYN-AKE is used for
SYN-AKE appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
SYN-AKE is the expression-line arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.